Things are slowly beginning to move ahead on our project to cure Alzheimer’s disease. It’s clear that not only is the role of microglia slowly becoming accepted, but there are more and more investors who see an opportunity to help move biotech and medicine from the old paradigm (BAPP and Tau cause disease) to the […]
0An odd thing is happening in the world of biotechnology: an avalanche is starting. The context is also interesting, for over the past twenty five years, a profound revolution has occurred in our understanding of aging. Where once we took aging for granted, we now reexamine the process, looking for a way to reverse it. […]
0Every several weeks, I notice publication of yet another article trumpeting another aspect of Alzheimer’s. Where once it was APOE-4, AB42, or SS31 (an antioxidant peptide), more recent work emphasizes arginine metabolism in the microglia. The good news is that research community has — ponderously and hesitantly — finally begun to shift the clinical focus […]
0At the moment, there are four companies planning human trials to reset telomeres using telomerase genes. In every case, the intent is to put the telomerase genes (hTERT and hTERC) into human patients in an effort to cure age-related diseases. Let’s look at the diseases and then the companies involved. Essentially, all age-related diseases occur […]
0